Curated News
By: NewsRamp Editorial Staff
June 05, 2025

NRx Pharmaceuticals to Acquire Kadima, Launch $100M Psychiatry Clinic Network

Reddit View History of this news story on GitHub
Original Source

TLDR

  • NRx Pharmaceuticals' acquisition of Kadima Neuropsychiatry Institute positions HOPE Therapeutics for rapid revenue growth and a competitive edge in the interventional psychiatry clinic network.
  • HOPE Therapeutics plans to expand to 30 interventional psychiatry clinics by 2025, leveraging Kadima's model and expertise to achieve a $100 million pro forma run rate.
  • The acquisition and expansion aim to enhance mental health treatment accessibility, offering hope and innovative solutions for conditions like bipolar depression and acute suicidality.
  • Dr. David Feifel joins HOPE as Chief Medical Innovation Officer, bringing Kadima's pioneering interventional psychiatry techniques to a broader audience through a national clinic network.

Impact - Why it Matters

This acquisition and the planned national clinic network represent a significant advancement in mental health treatment, particularly for conditions like bipolar depression and acute suicidality. By leveraging Kadima's expertise in interventional psychiatry and NRx's innovative treatments, this initiative could dramatically improve patient outcomes and access to specialized care. The involvement of Dr. David Feifel as Chief Medical Innovation Officer further underscores the potential for groundbreaking developments in mental health services. This news is crucial for investors, healthcare professionals, and patients alike, signaling a transformative shift in how mental health conditions are treated and managed.

Summary

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company renowned for its treatments targeting suicidal bipolar depression and acute suicidal depression, has announced a definitive agreement to acquire Kadima Neuropsychiatry Institute. This strategic move is part of NRx subsidiary HOPE Therapeutics' ambitious plan to establish a national network of interventional psychiatry clinics, aiming for a $100 million pro forma run rate by the end of 2025. The acquisition is expected to immediately boost NRx and HOPE's revenue and EBITDA. Kadima, a leader in interventional psychiatry based in La Jolla, California, will serve as the clinical and operational blueprint for the proposed network. Dr. David Feifel, Kadima's founder, is set to join HOPE as Chief Medical Innovation Officer, bringing his expertise to the forefront of this innovative venture. NRx's broader pipeline includes FDA-designated treatments for bipolar depression and acute suicidality, underscoring the company's commitment to addressing critical mental health challenges. For more details, visit Read More>>.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NRx Pharmaceuticals to Acquire Kadima, Launch $100M Psychiatry Clinic Network

blockchain registration record for this content.